Currently Viewing:
Newsroom
Currently Reading
Current Risk-Adjustment Approach Underpaid Insurance Carriers for Part-Year Members
February 24, 2018 – Kaitlynn Ely
Survey Examines Whether Primary Care Doctors Gave Correct ADHD Diagnosis
February 23, 2018 – Allison Inserro
This Week in Managed Care: February 23, 2018
February 23, 2018
5 Things to Know About Biosimilars and Inflammatory Bowel Disease
February 23, 2018 – Kelly Davio
Hydroxychloroquine Ineffective in Treating Hand Osteoarthritis Compared With Placebo
February 23, 2018 – Kaitlyn Ely
AJMC® in the Press, February 23, 2018
February 23, 2018 – AJMC Staff
What We're Reading: GAO Slams CMS; Walker Gets Friendly Toward ACA; Opioid Bills in House
February 23, 2018 – AJMC Staff
Employer-Sponsored Wellness Programs Attract Already Fit and Healthy Individuals
February 23, 2018 – Kaitlynn Ely
FDA Warns About Risks of Biaxin in Patients With Cardiac Disease
February 22, 2018 – Allison Inserro

MSK and PathoQuest Test Method to Detect Infection in Patients With Febrile Neutropenia

AJMC Staff
A new collaboration between PathoQuest and Memorial Sloan Kettering Cancer Center (MSK) will test the best method to identify microorganisms responsible for infections in patients with febrile neutropenia.
A new collaboration between PathoQuest and Memorial Sloan Kettering Cancer Center (MSK) will test the best method to identify microorganisms responsible for infections in patients with febrile neutropenia.

MSK will test PathoQuest’s iDTECT Blood test and compare it with the standard testing methods. The iDTECT Blood test is a CE-IVD test based on next-generation sequencing that allows clinicians to detect bacteria and viruses in blood samples from immunocompromised patients with suspected infections.

“This study will add to the clinical evidence we have accumulated to date which demonstrates the improved ability to identify bacteria and virus from blood samples using next-generation sequencing technology in combination with our proprietary iDTECT Blood sample preparation process and bioinformatics solution,” Jean-Francois Brepson, PathoQuest’s CEO, said in a statement.

The current standards for diagnosing microorganisms in immunocompromised patients that may cause infection are not “timely or effective,” said Yi‐Wei Tang, MD, PhD, chief of the Clinical Microbiology Service at MSK, and professor of Pathology and Laboratory Medicine at the Weill Medical College of Cornell University.

Patients who are potentially immunosuppressed from chemotherapy have an increased risk of infection from bacteria such as Mycobacterium and Clostridium difficile. As patients’ absolute neutrophil count falls, the risk of serious infection increases. PathoQuest believes that its test offers an improved method for detecting bacteria in blood samples, which can lead to better treatment.

“This collaboration will enable the identification of bacteria and viruses responsible for infections and aligns with our mission to improve the quality of care for patients,” Tang said.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!